Sotagliflozin, a dual sodium-glucose cotransporter-1 and 2 (SGLT 1 and 2) inhibitor, protects the kidneys and heart in patients with type 2 diabetes and chronic kidney disease. The drug reduced the risk of dialysis, kidney transplantation, reduction in estimated glomerular filtration rate, cardiovascular complications and death.
Researchers from the University of Toronto have proven the effectiveness and safety of sotagliflozin in patients with type 2 diabetes and chronic kidney disease. The study results, which will be presented at the annual meeting of the American Society of Nephrology ASN Kidney Week 2023, were published by MecalXpress.
In the sotagliflozin group, there was a combined risk, including a deterioration in estimated glomerular filtration rate, a decrease in this indicator below 15 ml/min/1.73 m2 and the need for dialysis was reduced by 50% or more. At the same time, there was a decrease in the likelihood of kidney transplantation by 38%. In addition, this group had a 23% reduction in the risk of cardiovascular events and mortality associated with cardiovascular disease or kidney disease.
|Data from 10,584 patients with type 2 diabetes mellitus, chronic kidney disease, and risk factors for cardiovascular complications were analyzed. Participants were divided into two groups: sotagliflozin or placebo. Renal and cardiac outcomes were assessed using laboratory parameters. The average follow-up duration was 16 months. A total of 223 adverse events were recorded.
The authors emphasized that sotagliflozin has previously been shown to reduce the risk of heart failure and ischemic events such as myocardial infarction or stroke. New data indicate additional cardioprotective and nephroprotective effects of the drug.